Trial · NCT00546754
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Change in Systolic Blood Pressure From Baseline to Week 6 | Baseline and Week 6 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 344 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | mm Hg | MEAN |
| SECONDARY | Change in Diastolic Blood Pressure From Baseline to Week 6 | Baseline and Week 6 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 344 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | mm Hg | MEAN |
| SECONDARY | Number of Patients Achieving Target Blood Pressure at Week 6 | Week 6 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 393 and 345 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | Patients | NUMBER |
| PRIMARY | Change in Systolic Blood Pressure From Baseline to Week 12 | Baseline and Week 12 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 371 and 331 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | mm Hg | MEAN |
| SECONDARY | Number of Patients Achieving Target Blood Pressure at Week 12 | 12 Weeks | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 372 and 332 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | Patients | NUMBER |
| SECONDARY | Time to Achieve Target Blood Pressure | 12 weeks | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 406 and 360 patients for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | Days | MEAN |
| SECONDARY | Change in Uric Acid From Baseline to Week 6 | Baseline and Week 6 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 298 and 269 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | umol/L | MEAN |
| PRIMARY | Change in Diastolic Blood Pressure From Baseline to Week 12 | Baseline and Week 12 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 371 and 331 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | mm Hg | MEAN |
| SECONDARY | Change in Uric Acid From Baseline to Week 12 | Baseline and Week 12 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 286 and 253 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | umol/L | MEAN |
| SECONDARY | Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 6 | Baseline and Week 6 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 304 and 272 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | mg/L | MEAN |
| SECONDARY | Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 12 | Baseline and Week 12 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 279 and 255 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | umol/L | MEAN |
| SECONDARY | Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 6 | Baseline and Week 6 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 300 and 273 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | IU/L | MEAN |
| SECONDARY | Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 12 | Baseline and Week 12 | 416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 279 and 254 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively | IU/L | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00546754/outcomes